OPEN MINDS
For experienced entrepreneurs, UnBox offers unique opportunities to partner with brilliant researchers to found transformational deep-tech startups. The UnBox Fast Track program offers founding teams a majority stake in their venture, sweeping intellectual property assignment, $100,000 in pre-seed funding, pre-seed office space and individual coaching and support through seed stage fundraising.
To inquire about one or more of the following opportunities, please complete the inquiry form below, and we will get back to you promptly.
For questions, please contact: Dr. Rotem Efrony
OPEN MIND PROJECTS
Clonal
Prof. Sol Efroni
Dr. Alona Zilberberg
Dr. Hagit Philip
The problem
Years of research at Israel’s Bar-Ilan University show the efficacy of the T-cell Repertoire as biomarker. We use these repertoire data and proprietary machine learning algorithms to, very effectively, detect cancer. We are now ready to develop diagnostic kits to detect cancer at an early stage.
Available methods for early detection are insufficient and do not provide the needed accuracy. Unlike current technologies, the immune system is able to detect these changes long before they present any clinical manifestation.
Clonal aims to deliver a reliable bio-marker map that would do just that.
The invention
The TCR repertoire provides a per-patient unique immune code, which reflects, in real-time, the immune system’s response to stimuli.
The TCR repertoire is composed of millions “clones” that make up each person’s individual code. We have translated these data into health status.
Few Patents are in PCT stage.
Emmesh
Prof. David Zitoun
Dr. Kobby Saadi
Moshe Johary, Business adviser
The problem
The climate crisis raised the interest in the integration of renewable energy sources, mainly solar fields, and wind turbines, as an alternative for the high polluted fossil fuels. The inherent instability of those sources turns the energy storage issues critical for effective usage. The exist Li-ion technology present limited and costly solution which prevent the completion of transition to environment-friendly sources. Storage solution will become mandatory demand for every large-scale energy producer. Every cost-effective and long-term solution will easily integrate into the energy supply chain and support the energy revolution.
The invention
Redox Flow battery (RFB) is an electrochemical energy converter which can store energy from renewable sources and supply it on demand. It uses abundant materials and decouple the dependence between power and energy, unlike alternative systems. RFB based storage system can provide an effective long term solution for long duration energy storage.
NanoSweets
Prof. Rachela Popovtzer
Chen Tzror-Azankot
The problem
NanoSweets develops innovative technology for targeted radiotherapy for cancer treatment. Radiation therapy (RT) is one of the most prominent and effective treatment for various types of cancer. However, RT comes with inherent limitations. First, in most cases it can only treat the primary tumor, and not distant metastasis. Second, its implementation is highly complicated, relying on specialized experts and extremely expensive equipment and facilities. NanoSweets aims to overcome these limitations, by developing a nano-based technology for systemic delivery of radiation therapy, which can specifically target both tumors and metastases by utilizing the unique characteristics of tumors and tumor vasculature.
The invention
The technology is based on biocompatible nanoparticles designed for the systemic administration of radiation therapy. These nanoparticles enable the attachment of different radionuclides to their surface and undergo modifications to actively target cancerous tissues and have a patented structure (US Patent Application No. 17/051,687)
SIGNIT.bio
Prof. Rachela Popovtzer
Dr. Shir Hochwald-Liber
Prof. Ehud Banin
Dr. Yosi Ben-David
Prof. Nitsan Maharshak - Head of IBD Unit at Tel Aviv Medical center
The problem
Crohn’s disease (CD) and ulcerative colitis (UC), also known as Inflammatory Bowel Diseases (IBD), present a major health challenge with a rising incidence worldwide. These chronic gut disorders, marked by recurrent flares, demand early detection and continuous monitoring. Distinguishing them from conditions like Irritable Bowel Syndrome (IBS), which lacks IBD complications, is crucial. Unfortunately, today there is no simple, rapid and non-invasive solution which accurately identifying IBD patients and facilitating early monitoring, hindering optimal disease management. SIGINT.bio offers bio-chip-based medical device, as a rapid, non-invasive solution for IBD monitoring, effectively distinguishing between IBD and IBS in their very early stages. This innovative technology stands to significantly advance monitoring and management of these complex conditions, paving the way for personalized medicine-based treatment.
The invention
SIGNIT.bio technology is based on the ability to detect biological signals secreted by the gut microbiome and evaluate their different presence in IBD conditions. For that end, we combine advanced synthetic biology together with electrochemistry and wireless communication methods to provide rapid, non-invasive, and highly sensitive detection and monitoring of IBD.
Patent- PCT
